× Business
TelecomHealthcareDigital MarketingERPRetailMedia and EntertainmentOil and GasFood and BeveragesMarketing and AdvertisingBanking and Insurance
Technology
Big DataCloudIT ServiceSoftwareMobileSecurityNetworkingStorageCyber SecuritySAPData AnalysisloTBio Tech
Platform
Cisco DATABASE Google IBM Juniper Microsoft M2M Oracle Red hat Saas SYMANTEC
Leadership
CEO ReviewCMO ReviewCFO ReviewCompany Review
Magazines
US ASIA ARCHIVE
Startups Opinion Yearbook Readers Speak Contact Us

10 Fastest Growing Pharma Companies 2016

“Our pipeline includes innovative product candidates that address the functional and behavioral needs of dementia patients”: Axovant Sciences

silicon-review-vivek-ramasamy

“Our greatest weakness lies in giving up. The most certain way to succeed is always to try just one more time” – Thomas A. Edison

Established with a vision to become the leading company focused on the treatment of dementia by comprehensively addressing the cognitive, functional, and behavioral needs of dementia patients, Axovant Sciences is a company whose pipeline includes innovative product candidates that address the needs of dementia patients. For years ahead, the company mission is to build a pipeline of late stage CNS drugs in a capital efficient manner to deliver value to patients and to shareholders.

Axovant’s Clinical Trials
Clinical trials are an important part of bringing new treatments to patients. By participating in a clinical trial, participants can gain access to new research treatments before they are widely available and help others by contributing to important medical research. Axovant is committed to providing treatments for all aspects of dementia and a list of our current clinical trials can be found below.

MINDSET TRIAL – MINDSET is a Phase 3 international, multi-center, double-blind, placebo-controlled clinical study designed to evaluate the safety, tolerability, and efficacy of RVT-101 in patients with mild-to-moderate Alzheimer’s disease.

The MINDSET Phase 3 trial is designed to confirm the results of a 684-patient international, multi-center, double-blind placebo-controlled study in which patients on a stable background of donepezil therapy receiving 35 mg RVT-101 demonstrated statistically significant improvements on the ADAS-cog and ADCS-ADL as compared to patients receiving donepezil alone.

HEADWAY-DLB – It is a Phase 2b multi-center, double-blind, placebo-controlled clinical study evaluating RVT-101 in patients with dementia with Lewy bodies (DLB).

Knowing the Key Executives

Mark Altmeyer, President & Chief Commercial Officer – Mark has three decades of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a particular focus on therapies for central nervous system disorders.

Served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc. from 2009-2014, leading 1,700 employees and growing total revenues from $2.6B to over $5B.

Led the launch of Abilify®, the top-selling CNS drug in history and the number one selling drug in the United States in 2013, he held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization and Senior Vice President, Neuroscience Business Unit.

He is an MBA from Harvard Business School, BA from Middlebury College.

Gregory M. Weinhoff, Chief Financial Officer – Dr. Weinhoff carries more than twenty years of experience in healthcare finance and operations, including as a venture capital investor, operating executive, and board member with Audit Committee experience.

Partner at CHL Medical Partners focused on investments into start-up and early-stage companies across therapeutics, diagnostics, medical devices and healthcare services.

Founding CEO of Amicus Therapeutics, subsequently member of Board Audit Committee. Founding President of VaxInnate, President of Resolvyx, he has also served.

In healthcare groups at J. H. Whitney & Co. and Morgan Stanley & Co.

Gregory is MD from Harvard Medical School, MBA from Harvard Business School (Baker Scholar), AB in Economics (magna cum laude) from Harvard College.

Vivek Ramaswamy, Chief Executive Officer – Vivek is the founder of Roivant Sciences, the parent company of Axovant Sciences, and serves as CEO of Axovant Sciences, Inc. He is also the Chairman of Arbutus Biopharma, a company focused on developing a cure for chronic hepatitis B virus infection. Prior to founding Roivant Sciences, Vivek was Partner at QVT Financial LP, where he was responsible for biotechnology investments. He also has prior experience as a successful entrepreneur in the technology industry.

Chairman of the Board for Arbutus Biopharmaceuticals, Inc., an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV).

Founder and President of Campus Venture Network, a technology company acquired in 2009.

AB in Biology (summa cum laude) from Harvard College and JD from Yale Law School.

A Brief on Dementia

Dementia is a general term for a group of symptoms caused by disorders that impair at least two brain functions, like memory or judgement. Alzheimer’s disease is the most common type of dementia. People with dementia have significantly impaired cognitive functioning which interferes with every day activities, such as getting dressed or eating. People suffering with dementia may also have behavioral problems, such as agitation, or experience delusions or hallucinations. While memory loss is a common symptom of dementia, memory loss alone does not lead to a diagnosis of dementia.

“We have assembled a team with decades of combined experience in developing, obtaining approval, and commercializing drugs for central nervous system disorder”

Pipeline of Axovant

  • Currently they are developing two novel compounds: RVT-101, a potent 5HT6 receptor antagonist, and nelotanserin, a highly potent and selective inverse agonist of the 5HT2A receptor.
  • Their near-term focus is to develop RVT-101 for the treatment of Alzheimer’s disease and dementia with Lewy bodies.
  • They are on the beginning of development of their second compound, nelotanserin, for the treatment of Lewy body dementia. In early 2016 they will initiate two separate Phase 2 studies of nelotanserin.

“Our mission is to build a pipeline of late stage CNS drugs in a capital efficient manner to deliver value to patients and to shareholders”

YOU MIGHT ALSO LIKE::

ENROLL FOR UPCOMING ISSUE